SEATTLE–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies to improve vision for people around the world, today announced the appointments of Tracy Valorie, former Senior Vice President and General Manager, US Ophthalmology Rx and Surgical at Bausch + Lomb, and Dwight Moxie, Senior Vice President, General Counsel and Corporate Secretary at Revance Therapeutics, Inc., to its Board of Directors.
“I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics’ Board of Directors,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Both of these renowned leaders possess expertise across many industries and will be invaluable as we continue to grow our portfolio of novel compounds and advance our lead program, BRIMOCHOL, in development for the treatment of presbyopia. I look forward to their strategic insights and contributions to achieve our mission of dramatically improving patients’ lives by developing differentiated best-in-class ophthalmic therapies.”
About Tracy Valorie
Tracy Valorie brings deep expertise with 25 years of experience in the pharmaceutical and biotech industries spanning strategic business counsel, commercial development, brand and customer marketing, and clinical development and research. Ms. Valorie previously served as Senior Vice President and General Manager of US Ophthalmology Rx and Surgical at Bausch + Lomb. Prior to that, she held numerous leadership positions at Pfizer where she led commercial development for the company’s global Ophthalmology Franchise, including Xalatan® and Xalacom® for glaucoma. In her previous roles, she was responsible for collaborating with enterprising companies and evaluating novel technologies for potential partnerships. She is currently on the advisory board of Ophthalmic World Leaders. Ms. Valorie holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the University of Connecticut.
“I am honored to join Visus Therapeutics’ Board of Directors and am looking forward to working with this talented and capable team,” said Tracy Valorie. “BRIMOCHOL has the potential to be a real-world solution for people living with presbyopia, and I am excited to be an integral part of the organization developing a best-in-class pipeline of ophthalmic products under Ben’s leadership.”
About Dwight Moxie
Dwight Moxie is the General Counsel, Senior Vice President and Corporate Secretary at Revance Therapeutics. Mr. Moxie leads legal, governance and compliance for the company, and brings more than two decades of experience in the biopharmaceutical and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Previously, he served as the Vice President, Deputy General Counsel at Ultragenyx and held various legal counsel positions at Allergan and GlaxoSmithKline. Throughout his career, Mr. Moxie has led teams in commercial operations, litigation, research and development, regulatory, product marketing, and mergers and acquisitions. He holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.
“I’m proud to be involved with a company that is dedicated to creating a new generation of best-in-class ophthalmic therapies,” said Dwight Moxie. “I look forward to working alongside Visus Therapeutics’ outstanding management team to advance the company’s lead investigational candidate for the treatment of presbyopia, BRIMOCHOL, and its robust pipeline of novel ophthalmic therapies.”
Capital Markets Day in New York City – August 31, 2021
The Company previously announced that it will host its first Capital Markets Day for investors, analysts and media on August 31, 2021, from 10:00 a.m. to 2:00 p.m. ET at Convene, 530 Fifth Avenue in New York City. The Capital Markets Day will include presentations from Ben Bergo, co-founder and chief executive officer, Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development, and Carey Powers, vice president of marketing, as well as key opinion leaders in ophthalmology and optometry with a focus on the company’s development pipeline and emerging advances in the treatment of presbyopia and other ophthalmic conditions. A live webcast of the presentation and question and answer sessions will be accessible under “Events & Presentations” in the News page of the company’s website at www.visustx.com. To register for the event, please visit the Visus 2021 Capital Markets Day registration site.
About Visus Therapeutics
Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter (@VisusTx) and Instagram.